公开(公告)号：US20240132499A1

公开(公告)日：2024-04-25

申请号：US18476249

申请日：2023-09-27

Applicant: FORMA Therapeutics, Inc.

Inventor： Alex J. Buckmelter ,  Justin Andrew Caravella ,  Hongbin Li ,  Matthew W. Martin ,  Steven Mischke ,  David James Richard ,  Angela V. West

IPC: C07D471/18 ,  C07D403/12 ,  C07D471/08 ,  C07D487/08 ,  C07D487/18 ,  C07D491/107

CPC classification number: C07D471/18 ,  C07D403/12 ,  C07D471/08 ,  C07D487/08 ,  C07D487/18 ,  C07D491/107

Abstract: The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.

公开(公告)号：US11254674B2

公开(公告)日：2022-02-22

申请号：US16946159

申请日：2020-06-08

Applicant: FORMA Therapeutics, Inc.

Inventor： Shawn E. R. Schiller ,  Torsten Herbertz ,  Hongbin Li ,  Bradford Graves ,  Steven Mischke ,  Angela West ,  Jennifer R. Downing ,  Anna Ericsson

IPC: C07D471/04

Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

公开(公告)号：US11247987B2

公开(公告)日：2022-02-15

申请号：US16753439

申请日：2018-10-05

Applicant: FORMA Therapeutics, Inc.

Inventor： Justin Caravella ,  Bingsong Han ,  Cuixian Liu ,  Stephanos Ioannidis ,  Alexandre Joseph Buckmelter ,  David James Richard ,  Matthew W. Martin ,  Steven Mischke ,  Scot Mente

IPC: C07D417/04 ,  C07D417/12 ,  C07C261/04 ,  C07D231/40 ,  C07D241/04 ,  C07D265/30 ,  C07D277/46 ,  C07D277/56

Abstract: The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Protease 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments. Chemical entities disclosed herein include compounds of Formula (II): wherein A, R2, R3, R4, Ra, Rc, Rd, Re, Rf, and m are defined herein.

公开(公告)号：US10913753B2

公开(公告)日：2021-02-09

申请号：US16077407

申请日：2017-02-13

Applicant: FORMA Therapeutics, Inc.

Inventor： David Joseph Guerin ,  Kenneth W. Bair ,  Justin A. Caravella ,  Stephanos Ioannidis, Jr. ,  David R. Lancia, Jr. ,  Hongbin Li ,  Steven Mischke ,  Pui Yee Ng ,  David Richard ,  Shawn E. R. Schiller ,  Tatiana Shelekhin ,  Zhongguo Wang

IPC: C07D519/00 ,  C07D495/04

Abstract: The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, R7, X, m, and n are described herein.

公开(公告)号：US20220162207A1

公开(公告)日：2022-05-26

申请号：US17669112

申请日：2022-02-10

Applicant: FORMA Therapeutics, Inc.

Inventor： Shawn E.R. Schiller ,  Torsten Herbertz ,  Hongbin Li ,  Bradford Graves ,  Steven Mischke ,  Angela West ,  Jennifer R. Downing ,  Anna Ericsson

IPC: C07D471/04

Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

公开(公告)号：US11292791B2

公开(公告)日：2022-04-05

申请号：US16647478

申请日：2018-09-14

Applicant: FORMA Therapeutics, Inc.

Inventor： Shawn E. R. Schiller ,  Torsten Herbertz ,  Hongbin Li ,  Bradford Graves ,  Steven Mischke ,  Angela V. West ,  Jennifer R. Downing ,  Anna Ericsson

IPC: C07D471/04 ,  C07D519/00 ,  A61P35/00

Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

公开(公告)号：US20200002332A1

公开(公告)日：2020-01-02

申请号：US16457596

申请日：2019-06-28

Applicant: FORMA Therapeutics, Inc.

Inventor： Shawn E.R. Schiller ,  Torsten Herbertz ,  Hongbin Li ,  Bradford Graves ,  Steven Mischke ,  Angela West ,  Jennifer R. Downing ,  Anna Ericsson

IPC: C07D471/04

Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

公开(公告)号：US20240150349A1

公开(公告)日：2024-05-09

申请号：US18463587

申请日：2023-09-08

Applicant: FORMA Therapeutics, Inc.

Inventor： Shawn E.R. Schiller ,  Torsten Herbertz ,  Hongbin Li ,  Bradford Graves ,  Steven Mischke ,  Angela V. West ,  Jennifer R. Downing ,  Anna Ericsson

IPC: C07D471/04 ,  A61P35/00 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D519/00

Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

公开(公告)号：US11787803B2

公开(公告)日：2023-10-17

申请号：US17669135

申请日：2022-02-10

Applicant: FORMA Therapeutics, Inc.

Inventor： Shawn E. R. Schiller ,  Torsten Herbertz ,  Hongbin Li ,  Bradford Graves ,  Steven Mischke ,  Angela V. West ,  Jennifer R. Downing ,  Anna Ericsson

IPC: C07D471/04 ,  C07D519/00 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D519/00

Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

公开(公告)号：US20220185806A1

公开(公告)日：2022-06-16

申请号：US17557215

申请日：2021-12-21

Applicant: FORMA Therapeutics, Inc.

Inventor： Justin Caravella ,  Bingsong Han ,  Cuixian Liu ,  Stephanos Ioannidis ,  Alexandre Joseph Buckmelter ,  David James Richard ,  Matthew W. Martin ,  Steven Mischke ,  Scot Mente

IPC: C07D417/12 ,  C07C261/04 ,  C07D231/40 ,  C07D241/04 ,  C07D265/30 ,  C07D277/46 ,  C07D277/56 ,  C07D417/04

Abstract: The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments.